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Abstract A C36 linear acetylene alcohol, lembehyne A (LB-A),
induces neuronal di¡erentiation against neuroblastoma cells
morphologically and also functionally. The di¡erentiation and
cytostatic e¡ect induced by LB-A was speci¢c to neuroblasto-
ma, Neuro 2A cells. To identify the target protein for LB-A, a
radioactive photoa⁄nity probe, [125I]18-(2P-azido-5P-iodo-ben-
zoyloxy)-LB-18 ([125I]azido-LB-18), was synthesized. As a re-
sult of in situ labeling experiments against Neuro 2A cells, a
protein of Mr 30 kDa was photolabeled speci¢cally. This label-
ing was inhibited in the presence of LB-A or the active analogs
of LB-A, whereas the inactive analogs showed no inhibitory
e¡ect on this labeling. These results suggest that this protein
of Mr 30 kDa is the target protein for LB-A and may play an
important role for the neuronal di¡erentiation in neuroblastoma,
Neuro 2A cells.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Di¡erentiation inducers against tumor cells are expected to
be new candidates for cancer chemotherapy, since tumor cells
retain ability to di¡erentiate in many cases [1]. These substan-
ces inducing di¡erentiation may exhibit selective activity
against tumor cells and minimal side e¡ects against normal
cells. Actually, clinical trials are in progress for retinoic acid
or its synthetic analogs as chemoprevention and therapeutic
agents in selected human cancers [2,3]. As the di¡erentiation
program might be disrupted in neuroblastoma cells, new dif-
ferentiation inducers for chemotherapy of various neuronal
diseases are expected to be worthwhile. So far, several di¡er-
entiation inducers with low molecular weight for neuroblasto-
ma have been reported [4^10]; however, the mechanism of cell
di¡erentiation induced by these inducers is still unclear.
A C36 long chain acetylene alcohol, lembehyne A (LB-A),
and its analogs, which induce neuritogenesis in a murine neu-
roblastoma cell line, Neuro 2A, and a rat pheochromocytoma
cell line, PC12, were found from a marine sponge of Haliclona
sp. [11,12] (Fig. 1). After LB-A treatment, Neuro 2A cells
brought out a morphological change with long bipolar pro-
cesses emanating from opposite sides of the cell body and a
functional change with increase of acetylcholinesterase [13].
LB-A was structurally a new type of di¡erentiation inducer
for these cells. LB-A also blocked the cell cycle of Neuro 2A
at the G1 phase in a concentration-dependent manner [13].
The structure^activity relationship study of LB-A clari¢ed
that the terminal 1-yn-3-ol moiety including 3R con¢guration
and the long alkyl chain in LB-A were required for neuronal
di¡erentiation-inducing activity [12]. In fact, the neuritogenic
activities of several analogs (3-O-methyl or 1-methyl deriva-
tives of LB-A, LB-10, having a short carbon-chain, and 3S-
LB-A, having a 3S con¢guration) were much weaker than
that of LB-A. On the other hand, LB-18 (C18 analog) and
LB-20 (C20 analog) showed stronger activity than LB-A. The
importance of the R-con¢guration at the C-3 chiral center for
neuritogenic activity implied the presence of a target protein
for LB-A. A crucial moiety of LB-A may be involved in
primary recognition of the target protein. On the basis of
this evidence, we undertook to identify the target protein
for LB-A.
Judging from the chemical structure of LB-A, formation of
a covalent bond between LB-A and the target protein seemed
to be di⁄cult. On the other hand, photoa⁄nity labeling,
which forms a covalent bond between a ligand and a recep-
tor protein forcibly under UV irradiation, is well known to
be a powerful technology for identifying a target protein
[14]. Thus, we synthesized a radioactive photoa⁄nity probe,
[125I]18-(2P-azido-5P-iodo-benzoyloxy)-LB-18 ([125I]azido-LB-
18), and performed a photolabeling experiment. This report
communicates the in situ labeling of the target protein for
LB-A.
2. Materials and methods
2.1. Materials
LB-A was isolated from a marine sponge of Haliclona sp., which
was collected at Lembeh Island, Bitung, Indonesia, as described pre-
viously [11]. LB-A analogs, LB-10, LB-18, LB-20, and 3S-LB-18, were
synthesized in our previous report [12,13].
2.2. Cell cultures
Murine neuroblastoma cell line, Neuro 2A, and ¢broblast derived
from Fischer rat embryos, 3Y1-B (clone 1-6), were grown in the Dul-
becco’s Modi¢ed Eagle’s medium supplemented with 10% fetal bovine
serum (FBS) and kanamycin (50 ng/ml). Human chronic myelogenous
leukemia cell line, K562, was grown in RPMI1640 medium supple-
mented with 10% FBS and kanamycin (50 ng/ml). All cells were kept
in an incubator at 37‡C with 5% CO2. The viability of cells was
determined by trypan blue exclusion.
2.3. Cell cycle analysis
Cells were treated with LB-A for 24 h at 37‡C with 5% CO2. The
harvested cells were washed with phosphate-bu¡ered saline (PBS)
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twice, then dyed by DNA-Prep Reagents kit (Coulter) for 20 min.
After removal of the supernatant by centrifugation (500Ug for 5
min), the resulting cell pellet was suspended in D-PBS(3) solution
and ¢ltered through 40-Wm nylon mesh ¢lter. The cell cycle analysis
of the ¢ltrate was carried out on FACSCalibur (Becton Dickinson,
Vex = 493 nm, Vem = 630 nm).
2.4. Western blotting of p21cip1/waf1
Cells were treated with LB-A for the indicated time at 37‡C with
5% CO2. The harvested cells were lysed in lysis bu¡er (20 mM Tris^
HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM L-glycerol phosphate,
1 mM Na3VO4, 1% protease inhibitor cocktail^DMSO solution (P-
8340, Sigma)). Cellular lysates were mixed with SDS^PAGE (sodium
dodecyl sulfate^polyacrylamide gel electrophoresis) sample bu¡er (100
mM Tris^HCl, 4% SDS, 12% mercaptoethanol, 20% glycerol, 0.005%
bromophenol blue), boiled for 5 min, and separated in 15^25% SDS^
polyacrylamide gels. Then the proteins were electrotransferred to
polyvinylidene di£uoride membrane (Amersham Pharmacia Biotech).
The blot was incubated with monoclonal anti-mouse p21cip1=waf1 anti-
body (Santa Cruz Biotechnology), and detection of p21 protein was
carried out with the enhanced chemiluminescence Western blotting
detection reagents (Amersham Pharmacia Biotech).
2.5. Preparation of photoa⁄nity probe,
18-(2P-azido-5P-iodo-benzoyloxy)-LB-18 (azido-LB-18)
Azido-LB-18 was synthesized by the route as shown in Scheme 1.
Benzoic acids 1 and 2 were synthesized from 5-iodoanthranilic acid as
described in the previous report [15]. The treatment of 16-hydroxy-
hexadecanoic acid with N,O-dimethylhydroxylamine hydrochloride
(MeONHMeWHCl), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
(EDCI) hydrochloride, and N,N-dimethylaminopyridine (DMAP)
and subsequent protection of the hydroxyl group at C-18 a¡orded
Weinreb amide 4 in 93% yield for two steps. The nucleophilic sub-
stitution for 4 with lithium (triisopropylsilyl (TIPS))acetylide provided
an alkyne 5 in 98% yield. Then, the asymmetric reduction of 5 using
(R)-2-methyl-CBS-oxazaborolidine [16,17] and borane methylsul¢de
complex followed by deprotection of the silyl group using tetrabutyl-
ammonium £uoride proceeded with high enantiomeric selectivity
(100% ee) to a¡ord an alcohol 7 in 86% yield for two steps. The
alcohol 7 was ¢nally coupled with the acid 1 and the resulting product
was puri¢ed by silica gel column chromatography (n-hexane-
EtOAc=8:1) to furnish azido-LB-18 in 71% yield. The structure of
azido-LB-18 was con¢rmed by the analysis of its nuclear magnetic
resonance (NMR) and mass spectrometric (MS) spectrum. Azido-
LB-18: Colorless powder, FAB MS: m/z 576 (M+Na)þ. HR-FAB
MS: m/z 576.1699: calculated for C25H36IN3O3Na. Found:
576.1685. 1H-NMR (500 MHz, CDCl3, N) : 8.12 (1H, d, J=1.8 Hz,
ArH), 7.79 (1H, dd, J=8.5, 1.8 Hz, ArH), 6.98 (1H, d, J=8.5 Hz,
ArH), 4.37 (1H, td, J=7.0, 1.8 Hz, H-3), 4.30 (2H, t, J=6.7 Hz, H-
18), 2.46 (1H, d, J=1.8 Hz, H-1), 1.77^1.70 (4H, m, H-4, 17), 1.45^
1.20 (H-5^16).
Neuritogenic activity of azido-LB-18 was examined according to
the neurite outgrowth assay as described in the previous report [13].
2.6. Preparation of [125I]azido-LB-18
The alcohol 7 was treated with the acid 2, EDCI, and DMAP, and
the resulting product was puri¢ed by silica gel column chromatogra-
phy (n-hexane-EtOAc=8:1) to furnish a compound 8 in 35% yield.
Compound 8: Colorless powder, FAB MS: m/z 592 (M+H)þ. HR-
FAB MS: m/z 592.2561: calculated for C28H46N3O3Sn. Found:
592.2572. 1H-NMR (500 MHz, CDCl3, N) : 7.89 (1H, d, J=1.2 Hz,
ArH), 7.61 (1H, dd, J=7.8, 1.2 Hz, ArH), 7.20 (1H, d, J=7.8 Hz,
ArH), 4.37 (1H, td, J=6.9, 1.8 Hz, H-3), 4.31 (2H, t, J=6.7 Hz, H-
18), 2.46 (1H, d, J=1.8 Hz, H-1), 1.79^1.70 (4H, m, H-4, 17), 0.31
(9H, s, ^Sn(CH3) 3).
To a solution of 10 Wg of the compound 8 in MeOH (30 Wl) were
added 0.7 mM PBS solution of chloramine T (36 Wl, pH 7.5) and the
water solution of Na125I (17 Wl, 0.5 mCi, Perkin-Elmer). The reaction
mixture was stirred for 50 min at 45‡C. Subsequently, the reaction
mixture was treated with 0.7 mM MeOH solution of NaI (24 Wl) at
45‡C for 100 min. After evaporation of the solvent by argon gas, the
residue was extracted with benzene, and the soluble portion was trans-
ferred to another vial. The production of [125I]azido-LB-18 (estimated
11 Ci/mmol) was detected by autoradiography, which showed the
same Rf value with azido-LB-18 on thin layer chromatography.
2.7. In situ labeling of cells with [125I]azido-LB-18
The cell suspension of 2U106 cells in 5 ml of the culture medium
was plated on a 10-cm dish and incubated for 3 h. Then, an ethanol
solution of [125I]azido-LB-18 was added to the cells at a ¢nal concen-
tration of 53 nM. The ethanol solutions of the competitors were
added 1 h or 7 h prior to the addition of [125I]azido-LB-18. After
incubation with [125I]azido-LB-18 for 3 h at 37‡C, the cells were
washed with PBS three times and irradiated with a hand-held UV
lamp (366 nm, 100 W, UVP) at a distance of 1 cm for 3 minU2 (1
min pause) in PBS on ice. The photolabeled cells were harvested into
a centrifuge tube and lysed in lysis bu¡er (20 mM Tris^HCl, 150 mM
NaCl, 1 mM EDTA, 0.1 mM Na3VO4, 0.1% Tween 80, 1% protease
inhibitor cocktail^DMSO solution (P-8340, Sigma)). After stirring
with a vortex mixer for 30 min, the lysate was centrifuged for 3
min at 500Ug, then the supernatants of the lysate were analyzed by
4^20% or 15^25% SDS^PAGE. The developed gel was dried and
exposed to imaging plate BAS-IP MS2040 (Fuji Film) for 24 h. The
radio-labeled protein bands were detected on a Bioimage Analyzer
BAS-1500 (Fuji Film).
3. Results and discussion
In our previous study, LB-A, a long chain acetylene alco-
hol, was revealed to induce neuronal di¡erentiation against
murine neuroblastoma, Neuro 2A cells, and rat pheochromo-
cytoma, PC12 cells, morphologically and also functionally at
low concentration [11,13]. LB-A was also found to arrest the
cell cycle of Neuro 2A cells at the G1 phase speci¢cally [13].
Neuronal di¡erentiation closely relates to the cell cycle. The
G1 arrest at the di¡erentiation stage appears to be a normal
cell response, since the endogenous nerve growth factor also
arrests the cell cycle at the same phase [18].
We further examined the e¡ect of LB-A on the cell cycles of
the ¢broblast and leukemia cells, which have quite di¡erent
physiological features compared with neuroblastoma. For cell
cycle analysis, £ow cytometric analysis was carried out at 24 h
after the addition of LB-A to Neuro 2A, rat ¢broblast 3Y1,
and human leukemia K562 cells grown by random culture.
The treatment with 1^10 WM concentration of LB-A showed
no e¡ect on the cell cycle of 3Y1 cells or K562 cells, while the
cell cycle of Neuro 2A cells was remarkably arrested at the G1
phase by the treatment with 1^3 WM concentration of LB-A
(Fig. 2).
The cell cycle is regulated positively by cyclins associated
with cyclin-dependent kinase (CDK) and negatively by cyclin-
dependent kinase inhibitor (CDKI), which inhibits kinase ac-
tivity of cyclin/CDK complex. CDKIs are classi¢ed into two
groups of INK4 family (p15, p16, p18, and p19) and CIP/KIP
family (p21, p27, and p57) based on their sequence similarities
and putative target genes. The latter is concerned in arrest of
Fig. 1. Chemical structures of LB-A and its analogs.
FEBS 27309 21-5-03
S. Aoki et al./FEBS Letters 544 (2003) 223^227224
cell cycle and induction of cell di¡erentiation [19]. We further
investigated whether the induction of CDKI, p21cip1=waf1 pro-
tein, increases in response to the stimulus of LB-A or not. The
induction of p21 protein was not observed in the untreated
Neuro 2A cells, while the expression of p21 was remarkably
raised after 24 h treatment with 3 WM concentration of LB-A
(Fig. 3). The neurite sprouting in Neuro 2A cells treated with
LB-A was synchronized with the expression of p21 protein.
This result indicated that the expression of p21 was related to
the di¡erentiation of Neuro 2A cells induced by LB-A. On the
other hand, the expression of p21 was not observed in K562
cells treated with LB-A. Besides, LB-A did not a¡ect the
di¡erentiation and proliferation of K562 cells (data not
shown), which have an ability to di¡erentiate into erythrocyte,
megakaryocyte or macrophage by the treatment with various
low molecular di¡erentiation inducers. Thus, the cytostatic
e¡ect of LB-A was unique to neuroblastoma.
Next, we turned our attention to identi¢cation of the target
molecule of LB-A in neuroblastoma to examine the action
mechanism of LB-A. The importance of the R-con¢guration
at the C-3 chiral center in LB-A for the activity might indicate
the presence of a target protein for LB-A. LB-A seems to be
di⁄cult to form a covalent bond with a target protein, since
the reactive functional group attacked by a nucleophile in the
target protein is absent in LB-A. A photoa⁄nity probe, which
has a photo-reactive functional group such as an aromatic
azide group, is able to form a covalent bond with the receptor
protein forcibly under UV irradiation. So, the introduction of
the 2P-azido-5P-iodo-benzoyloxyl group at C-18 in LB-18,
which showed the strongest neuritogenic activity among lem-
behyne analogs, was designed. The non-radioactive photoaf-
¢nity probe, azido-LB-18 was synthesized from 16-hydroxy-
hexadecanoic acid e⁄ciently (Scheme 1). This analog
exhibited strong neuritogenic activity against Neuro 2A cells
at 1 WM the same as LB-A, indicating that this probe has an
a⁄nity to the target protein for LB-A. Hence, the radioactive
photoa⁄nity probe, [125I]azido-LB-18, was used to photolabel
the target protein for LB-A.
In situ photoa⁄nity labeling was carried out in Neuro 2A
cells 3 h after the treatment with 53 nM concentration of
[125I]azido-LB-18. Labeled cells were lysed in lysis bu¡er,
then the cell lysate was analyzed by SDS^PAGE and auto-
radiography. As a result of this labeling experiment, a protein
of Mr 30 kDa was speci¢cally photolabeled (Fig. 4). The
labeling of this protein was completely inhibited by the pre-
incubation of Neuro 2A cells with a 1^5 WM concentration of
LB-A, LB-18, or LB-20 having neuritogenic activity (Fig.
4A,B). The pre-incubation time with LB-A required for the
inhibition of labeling was much longer than that with LB-18
or LB-20. This result might be deduced to be due to the slow
incorporation of LB-A into cells. The pre-incubation with the
inactive analog, LB-10, at 1^5 WM concentration showed no
inhibition for this labeling. The slightly active analog, 3S-LB-
18, showed only weak inhibition for this labeling at 5 WM
concentration. These results strongly suggest that this protein
of Mr 30 kDa is the target protein, which mediates the neuro-
nal di¡erentiation in Neuro 2A cells.
Scheme 1. The synthesis of [125I]azido-LB-18. Reagents: (a)
MeONHMeWHCl, DMAP, EDCIWHCl, DMF, 95%; (b) TBDPSCl,
imidazole, DMF, 99%; (c) Li (TIPS) acetylide, THF, 98%; (d) (R)-
oxazaborolidine, BH3W(CH3)2S, THF, 98% (100% ee); (e) TBAF,
THF, 88%; (f) 1, DMAP, EDCIWHCl, THF; (g) 2, DMAP, ED-
CIWHCl, THF; (h) Na125I, chloramine T, MeOHWH2O.
Fig. 2. The e¡ect of LB-A on the cell cycle of various cells. Various cells were exposed to LB-A at the indicated concentration for 24 h, and
cell cycle distribution was determined. Triplicate experiments concurred with the same result.
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In general, cell lysate has been used as the labeling source
for photoa⁄nity labeling experiments, since the e⁄cacy of
photolabeling using whole cells was very poor. Fortunately,
we succeeded in in situ photoa⁄nity labeling in Neuro 2A
cells. Then, this labeled protein was strongly supported to
be a target protein for LB-A. Furthermore, the known di¡er-
entiation inducers for Neuro 2A cells, mevinolin [4], ganglio-
side GD1a [5], retinoic acid [6], staurosporine [7], and lacta-
cystin [9], did not inhibit this labeling by [125I]azido-LB-18 up
to 10 WM concentration. We also tried the photolabeling of
Fig. 3. The e¡ect of LB-A on the expression of p21cip1=waf1 in Neuro
2A cells. Whole cell extract was prepared at the indicated times
after treatment with 3 WM of LB-A and subjected to SDS^PAGE.
Immunoblotting was performed with anti-p21cip1=waf1 antibody. Trip-
licate experiments concurred with the same result.
Fig. 4. In situ photoa⁄nity labeling of the target protein for LB-A. Neuro 2A cells were photolabeled with 53 nM of [125I]azido-LB-18 after
1 h (panel A) or 7 h (panel B) incubation with various competitors. Whole cell extracts were analyzed by 15^25% SDS^PAGE and autoradi-
ography. K562 cells or 3Y1 cells were treated the same as Neuro 2A cells in the absence of competitors, and whole cell extracts were analyzed
by 15^25% SDS^PAGE and autoradiography (panel C). Triplicate experiments for panels A and B and duplicate experiments for panel C con-
curred with the same result.
FEBS 27309 21-5-03
S. Aoki et al./FEBS Letters 544 (2003) 223^227226
the target protein using K562 cells and 3Y1 cells; however, no
protein was labeled by [125I]azido-LB-18 under the same con-
ditions for Neuro 2A cells (Fig. 4C). These facts show that the
action mechanism of LB-A in Neuro 2A cells is di¡erent from
those of the known di¡erentiation inducers and the target
protein for LB-A seems to be not ubiquitous in various cells.
In conclusion, the photoa⁄nity labeling by [125I]azido-LB-
18 clari¢ed that the protein of Mr 30 kDa is a molecular
target for LB-A. This labeled protein may be responsible for
the neuronal di¡erentiation induced by LB-A, since this pro-
tein was not labeled in other cell lines, ¢broblast or leukemia,
which are non-responsive to LB-A. The photoa⁄nity probe,
[125I]azido-LB-18, is expected to be a useful tool for studying
the action mechanism of LB-A, which is di¡erent from those
of the known di¡erentiation inducers. LB-A has a simple
chemical structure and potent neuronal di¡erentiation activ-
ity, so it might be a good lead compound for di¡erentiation
therapy. Further study is needed for the characterization of
the protein of Mr 30 kDa and the elucidation of its role for
the neuronal di¡erentiation in Neuro 2A cells.
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